TY - JOUR
T1 - Randomized comparison of two chemotherapy, radiotherapy schemes for stage III and IV unresectable squamous cell carcinoma of the head and neck
AU - Merlano, Marco
AU - Rosso, Riccardo
AU - Sertoli, Mario Roberto
AU - Benasso, Marco
AU - Bacigalupo, Almalina
AU - Ardizzoni, Andrea
AU - Mereu, Paola
AU - Margarino, Giovanni
AU - Scala, Marco
AU - Vitale, Vito
AU - Corvö, Renzo
AU - Grimaldi, Andrea
AU - Pallestrini, Eugenio
AU - Barbieri, Marco
AU - Accomando, Emilio
AU - Scasso, Felice
AU - Novella, Vittorio
AU - Sampietro, Maurizio
AU - Fracchia, Paolo
AU - Brema, Fulvio
AU - Moratti, Maurizio
AU - Santi, Leonardo
PY - 1990
Y1 - 1990
N2 - Between August 1983 and December 1986,116 previously untreated patients with squamous cell carcinoma of the head and neck were randomized to receive induction chemotherapy followed by radiotherapy given in conventional fractions (55 patients, arm A) or an alternating chemotherapy and radiotherapy (3 courses of 20 Gy, 10 daily fractions each; 61 patients, arm B). The same chemotherapy was used in both arms: 6 mg/m2 vinblastine sulfate, hour 0; 30 mg bleomycin, hour 6; 200 mg methotrexate, hours 24 to 26; 45 mg leucovorin, hour 48. Forty-five patients had stage III disease and 71 had stage IV disease. All patients were evaluated for survival, 112 for toxicity, and 105 for analyses of response and time from the start of treatment until progression of disease. At the end of the combined treatment, we observed an overall response rate of 52% in arm A and an overall response rate of 64.9% in arm B. The incidence of mucositis was more relevant in arm B compared to arm A (P
AB - Between August 1983 and December 1986,116 previously untreated patients with squamous cell carcinoma of the head and neck were randomized to receive induction chemotherapy followed by radiotherapy given in conventional fractions (55 patients, arm A) or an alternating chemotherapy and radiotherapy (3 courses of 20 Gy, 10 daily fractions each; 61 patients, arm B). The same chemotherapy was used in both arms: 6 mg/m2 vinblastine sulfate, hour 0; 30 mg bleomycin, hour 6; 200 mg methotrexate, hours 24 to 26; 45 mg leucovorin, hour 48. Forty-five patients had stage III disease and 71 had stage IV disease. All patients were evaluated for survival, 112 for toxicity, and 105 for analyses of response and time from the start of treatment until progression of disease. At the end of the combined treatment, we observed an overall response rate of 52% in arm A and an overall response rate of 64.9% in arm B. The incidence of mucositis was more relevant in arm B compared to arm A (P
UR - http://www.scopus.com/inward/record.url?scp=0025320899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025320899&partnerID=8YFLogxK
M3 - Article
C2 - 1691811
AN - SCOPUS:0025320899
VL - 100
SP - 531
EP - 535
JO - Laryngoscope
JF - Laryngoscope
SN - 0023-852X
IS - 5
ER -